2KOCAK N, OZOGUL C. The effects of intravitreally injected bevacizumab on the retina and retina pigment epithelium: ex- perimental in-vivo electron microscopic study in intact versus vitrectomized eyes [ J ]. Cent Eur J Med,2010,5 (6) :745-751.
3SAXENA S,JAIN A. in "in vivo" histology of retina in bilat- eral chronic central serous chorioretinopathy after intravit- real bevacizumab [J].J Ocular Biol Dis Informatics , 2011,4 (4) :137-140.
4MITCHELL P. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab [J]. Curr Med Res Opin ,2011,27 : 1465-1475.
6SUN HJ, CHOi KS, LEE SJ. Adjunctive effect of intravitreal bevacizumab prior to lens-sparing vitrectomy in aggressive posterior retinopathy of prematurity : a case report [J]. Jpn J Ophthalmol,2012,56(5) :475-480.
7FORBES JM,THALLAS V,THOMAS MC,FOUNDS HW,BURNS WC,JERUMS G. The breakdown of preexisting advanced glycation end products is associated with reduced renal fi- brosis in experimental diabetes [J]. FASEB J,2003,17 ([2) : 1762-1764.
8KLETTNER A, ROIDER J. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro : efficiency and possi- ble additional pathways[J]. IOVS,2008,49 (10) :4523-4527.
9TAVERNA M, GENETIC J. Epidemiology of diabetic retinop- athy [J]. Exp Rev Ophthamlol ,2008 ,3 ( 2 ) : 165-175.
10DI LAURO R, DE RUGGIERO P, DI LAURO R, DI LAURO MT, ROMANO MR. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy [J].Graefes Arch Clin Exp Ophthalmo1,2010,248 ( 6 ) :785-791.
